Insider Transactions Reported by 27 Insiders of Spyre Therapeutics, Inc.

Symbol
SYRE on Nasdaq
Location
Waltham, MA

Insiders trading volume in the past year

Spyre Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Cameron Turtle Chief Executive Officer, Director $20.5M -$1.49M -6.76% 01 Dec 2025
MICHAEL HENDERSON Director $3.87M 29 May 2025
Scott L. Burrows Chief Financial Officer $1.59M -$300K -15.8% 02 Sep 2025
Jeffrey W. Albers Director $1.01M 29 May 2025
Anthony G. Quinn President & CEO, Director $580K 16 Mar 2022
Marcio Souza Director $63.9K 25 Aug 2022
Hunter C. Smith Director 22 Jun 2023
Jr. Michael Conick Hanley Chief Business Officer 23 Feb 2023
BAKER BROS. ADVISORS LP Director 08 Jun 2021
Alison Frances Lawton Director 22 Jun 2023
Russell J. Cox Director 22 Jun 2023
Armen Shanafelt Director 07 Jun 2022
Jonathan Alspaugh President and CFO 22 Jun 2023
Ivana Magovcevic-Liebisch Director 22 Jun 2023
Steven Weber VP, Controller&Princ Acctg Off 17 Feb 2022
V. BRYAN LAWLIS Director 07 Jun 2022
James Paul Kastenmayer General Counsel 23 Feb 2023
Linda L. Neuman Chief Medical Officer 23 Feb 2023
Jeff Marc Goldberg President and CEO, Director 29 Nov 2022
Leslie Sloan Chief Operating Officer 23 Aug 2022
Sandesh Mahatme Director 07 Jun 2022
Sandra Milligan Director 29 May 2025
Laurie Stelzer Director 29 May 2025
Heidy King-Jones Chief Legal Officer and Corporate Secretary 15 Jan 2025
Mark C. McKenna Director 29 May 2025
Sheldon Sloan Chief Medical Officer 15 Jan 2025
Fairmount Funds Management LLC Director 29 May 2025

Recent Insider Transactions by Companies or Individuals for Spyre Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.